Vol. 6 No. 3 (2026)
Reimbursement Reviews

Trastuzumab Deruxtecan (Enhertu)

decorative image of the issue cover

Published March 13, 2026

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses trastuzumab deruxtecan (Enhertu), powder for concentrate for solution for IV infusion (infusion/100 mg/vial).
  • Indication: Proposed: For treatment of adult patients with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) or HER2-ultralow (IHC 0 with membrane staining) breast cancer who have received at least 1 endocrine therapy in the metastatic setting.